PAREXEL Continues Expansion of Site Alliance Network
Global network accelerates patient recruitment and clinical trial start-up times
PAREXEL announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients’ clinical trials worldwide.
To address challenges in patient recruitment, PAREXEL developed its Site Alliance network, currently consisting of more than 180 members plus several SMOs, together providing access to approximately 6,000 investigators worldwide. The SMOs alone have a combined database of 7.5 million patients in more than 25 countries. The network is currently in all the major regions where PAREXEL runs clinical trials, and is expanding to 200 sites. The network’s size and scope fosters strategic collaboration between PAREXEL and sites on behalf of clients and ensures quality across multiple sites.
Read the full release here.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
